Understanding why individuals with Down syndrome are highly predisposed to autoimmunity has broad mechanistic and therapeutic implications. New work identifies novel potential mechanistic pathways driving increased autoimmunity-relevant CD11c+ B cells and provides the broadest view to date of the repertoire of autoantibodies generated in individuals with Down syndrome.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Antonarakis, S. E. et al. Down syndrome. Nat. Rev. Dis. Primers 6, 9 (2020).
Araya, P. et al. Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity. Proc. Natl Acad. Sci. USA 116, 24231–24241 (2019).
Lambert, K. et al. Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity. Sci. Transl Med. 14, eabi4888 (2022).
Sullivan, K. D. et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci. Rep. 7, 14818 (2017).
Sullivan, K. D. et al. Trisomy 21 consistently activates the interferon response. eLife 5, e16220 (2016).
Malle, L. et al. Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells. Nature 615, 305–314 (2023).
Pellegrini, F. P. et al. Down syndrome, autoimmunity and T regulatory cells. Clin. Exp. Immunol. 169, 238–243 (2012).
Rubtsova, K., Rubtsov, A. V., Cancro, M. P. & Marrack, P. Age-associated B cells: a T-bet-dependent effector with roles in protective and pathogenic immunity. J. Immunol. 195, 1933–1937 (2015).
Alpert, A. et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat. Med. 25, 487–495 (2019).
Santoro, J. D., Filipink, R. A., Baumer, N. T., Bulova, P. D. & Handen, B. L. Down syndrome regression disorder: updates and therapeutic advances. Curr. Opin. Psychiatry 36, 96–103 (2023).
Acknowledgements
The authors would like to thank A. Hocking for their helpful comments on this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.K. consults for TeraImmune and serves on the board for FreshTracks Therapeutics outside the submitted work. J.H.B. is a Scientific Co-Founder for GentiBio and Scientific Advisory Board member for GentiBio, a consultant for Bristol-Myers Squibb and Hotspot Therapeutics and has past and current research projects sponsored by Amgen, Bristol-Myers Squib, Janssen, Novo Nordisk, and Pfizer. J.H.B is a member of the Scientific Advisory Boards for La Jolla Institute for Immunology, Oklahoma Medical Research Foundation, a Section Editor for UpToDate, and owns stock in Omeros and Gentibio outside the submitted work.
Rights and permissions
About this article
Cite this article
Khor, B., Buckner, J.H. Down syndrome: insights into autoimmune mechanisms. Nat Rev Rheumatol 19, 401–402 (2023). https://doi.org/10.1038/s41584-023-00970-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41584-023-00970-0
